Reply: Biomarkers of ‘acute-onset’ chronic inflammatory demyelinating polyneuropathy

Sir,‘In my end is my beginning’ ∼ T.S. Eliot, East Coker In keeping with the quotation by T.S. Eliot, the clear delineation of CIDP phenotypic variants remains a difficult and often circular process. The search for antigenic targets in CIDP has continued for almost 30 years, but to date there is still no well-defined link between molecular targets and particular phenotypes. Although Devaux and colleagues (2012) identified 30% of CIDP patients with antibodies to nodal antigens, the precise molecular antigenic target was not identifiable in most patients. In line with the comments from Miura and colleagues, we agree that identification of pathogenic antigens will improve treatment and management for CIDP patients. Similar to the approaches as outlined by Miura and colleagues, our group and many others have been investigating potential antigenic targets in CIDP (Yan et al. , 2001; …